The global lung cancer therapeutics market size attained a value of USD 35.62 Billion in 2025. The market is likely to grow at a CAGR of 11.60% during the forecast period of 2026-2035 to attain a value of USD 106.74 Billion by 2035.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
11.6%
Value in USD Billion
2026-2035
*this image is indicative*
Cancer refers to multiple tumours that can start developing in one of the body parts and spread uncontrollably to other parts of the body. Tumours are lumps of tissue which are often identified as the initial symptoms of cancer. In the later stages, when the cancerous cells spread abnormally to other organs, it becomes extremely difficult to treat them. This process is known as metastasis. One of the primary causes of lung cancer is smoking. It can also happen due to using other types of tobacco and inhaling secondhand smoke or due to genetic factors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Companies have started to combine cancer treatment with machine learning. This will help the specialists identify cancer more efficiently with the CT scans.
The rapid industrialisation in developing countries has propelled the disposable incomes of the population, which can augment the healthcare market and show positive opportunities for the expansion of lung cancer therapeutics.
The development and implementation of nanomedicine can open up new opportunities for the market players and further propel the market development. This method of treatment will target the specific cancer cells for treatment and reduce the adverse effects of therapeutics.
Cancer therapeutics and technologies require skilled and trained professionals for the proper management of the systems.
The devices for cancer therapeutics require extensive amounts of money for maintenance and installation, which can be a hindering factor as smaller health institutions would avoid investing in these technologies.
Inadequate infrastructure and standardisation can hinder cancer care delivery, ultimately hindering the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The EMR’s report titled “Global Lung Cancer Therapeutics Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Breakup by Cancer Type
Breakup by Therapy
Breakup by Therapy Type
Breakup by End User
Breakup by Distribution Channel
Breakup by Region
Based on type, the market segments include non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Non-small cell lung cancer develops at a slower rate than small-cell lung cancer. The cancer cells in this type are larger compared to the other type. It is the most common type of lung cancer, accounting for a major percentage of lung cancer cases.
Small-cell lung cancer spreads faster than non-small cell lung cancer and there are chances that this type of cancer can come back after treatment. This type of lung cancer is the least common type of lung cancer.
Based on therapies, chemotherapy and radiation therapy hold a significant share of the market as they are the primary type of treatment given to patients. Chemotherapy is a type of cancer treatment conducted by using powerful drugs to kill fast-spreading cells or reduce the symptoms and prolong life.
Radiation therapy involves doses of radiation to kill cancer cells or slow down their growth by damaging their DNA. The treatment focuses on a particular body part where cancer cells are present.
Other treatments include immunotherapy and targeted therapy. Immunotherapy treatment utilises our body’s own immune system’s capabilities to control and treat cancer. It conditions our immune system to identify and attack cancer cells. It strengthens our immune system to fight against cancer cells if they return.
Targeted therapy as a type of cancer treatment utilises drugs to target the specific cells and proteins which help in the growth of cancer.
The lung cancer therapeutics market has several end-users including hospitals, homecare, and speciality clinics, among others. Among these segments, hospitals hold the largest share of the market.
With developing health infrastructure, larger hospitals are equipped with the latest technologies such as Gamma Cameras, PET/CT, CT simulation, and MRI (Magnetic Resonance Imaging), among others, for the diagnosis and treatment of cancer.
Cancer homecare is a specialised care service provided to patients as they deal with a lot of side effects. This service allows the patients to stay in a familiar environment with their families while receiving care from specialist.
Cancer speciality clinics are centres with specialised equipment and trained staff for the treatment of different types of cancer. Many developing countries are developing specialised clinics due to the increasing number of cases.
Based on distribution channels, the market segments include retail pharmacies, hospital pharmacies, and online pharmacies. Among these distribution channels, hospital pharmacy is expected to hold a significant share due to the increasing number of cases in hospitals.
Retail pharmacies are also growing in the market owing to the increasing preference of people to buy medicine from nearby stores. Online pharmacy is expected to hold a higher growth rate due to the rapid growth of the e-commerce industry.
The extensive E.M.R. report provides an in-depth evaluation of the market based on Porter's five forces model and a SWOT analysis The lung cancer therapeutics market report comprehensively analyses key players in the market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
Genentech, Inc. is a biotechnology company based in the United States. They became a part of the Roche Group in March of 2009. They function independently within Roche.
AstraZeneca PLC is a multinational company working in the field of pharmaceuticals and biotechnology, with a focus on developing and commercialising prescription medicines. Their areas for medicine development include Oncology, Cardiovascular and Metabolic Disease (CVMD) and Respiratory. They also collaborate with biotech research institutes to work with emerging technologies such as Modified RNA and CRISPR genome editing.
Novartis AG. is a Swiss multinational pharmaceutical company with a focus on creating treatments with science and technology in various sectors such as oncology, ophthalmology, neuroscience, and cardiovascular disorders, among many others. Novartis is also engaged in radioligand therapy, precision imaging, and gyroscope therapeutics.
Merck KGaA is a multinational company for science and technology with operations in different sectors such as healthcare, life science and electronics. They design and develop medicines and smart devices to treat diseases such as cancer and multiple sclerosis.
F. Hoffmann-La Roche Ltd is more commonly known as Roche. It is a multinational healthcare company based in Switzerland. They operate worldwide focusing on two sectors pharmaceuticals and diagnostics. They have started to focus on personalised healthcare with early detection of diseases and accurate diagnosis.
Boehringer Ingelheim International GmbH is a leading biopharmaceutical company, working with professionals on the latest innovation for the diagnosis of diseases for human health. The company works on drug discovery and development, and other healthcare products for heart diseases, metabolic diseases, cancer, lung diseases, mental disorders, and retinal diseases.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other Global Lung Cancer Therapeutics market key players are Agennix AG, Eli Lilly and Company, Sanofi-Aventis, GlaxoSmithKline, Hoffman-La Roche and among others.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The lung cancer therapeutics market was valued at USD 35.62 Billion in 2025.
The market is expected to grow at a CAGR of 11.60% from 2026 to 2035 to reach a value of USD 106.74 Billion by 2035.
The lung cancer therapeutics market is driven by the rising development of technology for treatment and diagnosis and an increasing number of cases due to the growth of the smoking population.
Governments are implementing plans to develop their healthcare infrastructure and organisations’ increasing focus on research and development to launch new and innovative treatment solutions are key trends in the market.
The regional markets for the global lung therapeutics market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
There are two main types of cancer available in the market for cancer therapeutics including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others.
The market segments for lung cancer therapeutics, based on therapy, include Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy, among others.
These therapeutics find end-uses in hospitals, home care, and speciality clinics, among others.
The distribution channels in the market for lung cancer therapeutics include hospital pharmacies, retail pharmacies, and online.
If surgery is excluded from the options, combined chemotherapy and radiation therapy is the primary treatment used for lung cancer. For advanced lung cancers, radiation therapy can help in relieving pain and slowing down the advancement of cancer.
The United States Food and Drug Administration has approved Lumakras (sotorasib) for the treatment of non-small cell lung cancer in adult patients whose tumours have a specific genetic mutation known as KRAS G12C.
The key players in the market include Genentech, Inc., AstraZeneca PLC, Novartis AG., Merck KGaA, F. Hoffmann-La Roche Ltd, and Boehringer Ingelheim International GmbH, among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Cancer Type |
|
| Breakup by Therapy |
|
| Breakup by Therapy Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share